Edith Cowan University

Research Online
ECU Publications Pre. 2011
1-1-2010

Lactate dyscrasia: a novel explanation for amyotrophic lateral
sclerosis
Sivan Vadakkadath Meethal
University of Wisconsin-Madison, Madison

Craig Atwood
Edith Cowan University

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks
Part of the Medicine and Health Sciences Commons
10.1016/j.neurobiolaging.2010.04.012
This is an Author's Accepted Manuscript of: Vadakkadath Meethal, S., & Atwood, C.S. (2010). Lactate dyscrasia: a
novel explanation for amyotrophic lateral sclerosis. NOTICE: this is the author’s version of a work that was
accepted for publication in Neurobiology of Aging. Changes resulting from the publishing process, such as peer
review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this
document. Changes may have been made to this work since it was submitted for publication. A version was
subsequently published in Neurobiology of Aging. Available here.
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks/6313

ARTICLE IN PRESS

Neurobiology of Aging xx (2010) xxx
www.elsevier.com/locate/neuaging

Lactate dyscrasia: a novel explanation for amyotrophic lateral sclerosis
Sivan Vadakkadath Meethala,b,e, Craig S. Atwooda,b,c,d,*
b

a
Geriatric Research, Education and Clinical Center, Veterans Administration Hospital, Madison, WI, USA
Section of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA
c
Case Western Reserve University, Cleveland, OH, USA
d
School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
e
Present address: Department of Neurological Surgery, University of Wisconsin-Madison, Madison, WI, USA

Received 19 December 2009; received in revised form 9 April 2010; accepted 13 April 2010

Abstract
Amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease) is a progressive debilitating neurodegenerative disease with no cure. We
propose a novel molecular model for the pathogenesis of ALS that involves an adenosine triphosphate (ATP)-dependent muscle neuronal
lactate shuttle (MNLS) at the neuromuscular junction (NMJ) to regulate the flow of lactate from muscle to neurons and vice versa. Failure
of the MNLS due to respiratory chain dysfunction is proposed to result in lactate toxicity and degeneration of nerve endings at the NMJ
leading to nerve terminus dysjunction from the muscle cell. At a critical threshold where denervation outpaces reinnervation, a vicious cycle
is established where the remaining innervated muscle fibers are required to work harder to compensate for normal function, and in so doing
produce toxic lactate concentrations which induces further denervation and neuronal death. This mechanism explains the exponential
progression of ALS leading to paralysis. The molecular events leading to the dysregulation of the MNLS and the dismantling of NMJ are
explained in the context of known ALS familial mutations and age-related endocrine dyscrasia. Combination drug therapies that inhibit
lactate accumulation at the NMJ, enhance respiratory chain function, and/or promote reinnervation are predicted to be effective therapeutic
strategies for ALS.
Published by Elsevier Inc.
Keywords: Amyotrophic lateral sclerosis; Lou Gehrig’s disease; LDH; Aspartate; Malate; Pyruvate; Oxaloacetate; Glutamate; Lactate; ATP; FALS; SALS;
Neuronal degeneration; Motoneuron; Neuromuscular junction; Lactate shuttle; Mitochondria; Respiratory chain; Muscular atrophy; Cu/Zn superoxide
dismutase 1; Hormone; Aging; Sex steroids; Estrogen; Progesterone; Testosterone

1. Introduction
Amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease) is a debilitating disease that is characterized by progressive neurodegeneration of motoneurons in the brain and
spinal cord. Initial manifestations are weakness of limbs, or
weakness in the bulbar region leading to abnormalities of
speech, swallowing difficulties, and facial weakness (Schmidt
et al., 2009). Eventually the loss of motoneurons results in
paralysis of voluntary muscles and to death by respiratory
failure within 1–5 years of onset of the disease.
* Corresponding author at: Wm. S. Middleton Memorial VA (GRECC
11G), 2500 Overlook Terrace, Madison, WI 53705, United States. Tel.: ⫹1
608 256 1901 ⫻ 11664.
E-mail address: csa@medicine.wisc.edu (C.S. Atwood).
0197-4580/$ – see front matter Published by Elsevier Inc.
doi:10.1016/j.neurobiolaging.2010.04.012

ALS is the most common form of motoneuron disease in
humans: a little over 5600 people in the USA are diagnosed
with ALS each year (incidence of 1–2 per 100,000 per
year). Although most cases of ALS typically develop between the ages of 40 and 70, it is often overlooked as being
an age-related disease with ethnic and gender predilections.
ALS is slightly more prevalent in men (60%) (Wijesekera
and Leigh, 2009).
The etiological mechanisms that underlie ALS are unclear, however 5%–10% of ALS cases are familial (FALS)
and in those families, there is a 50% chance that each
offspring will inherit the genetic mutation and develop the
disease (Beghi et al., 2006; Mitchell and Borasio, 2007).
However, the underlying gene defect in most patients with
FALS is unknown and 90% of all cases have no family
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history of ALS and are considered sporadic ALS (SALS).
The pathophysiology of ALS has been postulated to involve
immune mechanisms (neuroinflammation and T-cell responses), glutamate-mediated excitotoxicity, oxidative stress, mitochondrial dysfunction, apoptosis, protein aggregation, and
aberrant axonal transport (Holmoy, 2008; Mantovani et al.,
2009; Pasinelli and Brown, 2006; Seksenyan et al., 2009;
Shaw, 2005; Wang et al., 2004).
1.1. Cellular and molecular pathogenesis of ALS
The neuropathology of ALS has been characterized from
postmortem analyses (Leigh et al., 1995). The major pathological features of ALS include: (1) degeneration of the
corticospinal tracts and extensive loss of lower motoneurons
or anterior horn cells (Garofalo et al., 1995; Ghatak et al.,
1986; Hughes, 1982); (2) degeneration and loss of Betz cells
and other pyramidal cells in the primary motor cortex
(Hammer et al., 1979; Maekawa et al., 2004; Udaka et al.,
1986); and (3) reactive gliosis in the motor cortex and spinal
cord (Ekblom et al., 1994; Kawamata et al., 1992; Murayama et al., 1991; Schiffer et al., 1996).
In addition to the loss of neurons, various types of inclusion bodies have been identified in degenerating neurons
and surrounding reactive astrocytes and are well demonstrated hallmarks of ALS (Barbeito et al., 2004). Ubiquitinated inclusions found in lower motoneurons of the spinal
cord and brainstem are the most common and specific type
of inclusion in ALS (Matsumoto et al., 1993) and in corticospinal upper motoneurons (Sasaki and Maruyama, 1994).
The exact composition of such inclusions, classified as
“Lewy body-like inclusions”, “Skein-like inclusions” (He
and Hays, 2004; Kawashima et al., 1998), and Bunina
bodies (Wada et al., 1999) is not known. However, the
proteins identified so far can include ubiquitin (Leigh et al.,
1991; Murayama et al., 1989), Cu/Zn superoxide dismutase
1 (SOD1) (Shibata et al., 1994, 1996), peripherin (He and
Hays, 2004), Dorfin (a RING-finger type E3 ubiquitin ligase) (Niwa et al., 2002), and more rarely synuclein (Sone
et al., 2005). Various studies conducted in ALS postmortem
tissue in the early nineties found accumulations of intermediate filament proteins (hyperphosphorylated neurofilament
subunits and peripherin) in hyaline conglomerate inclusions
and axonal “spheroids” in spinal cord motoneurons (Corbo
and Hays, 1992; Munoz et al., 1988; Sobue et al., 1990), and
pyramidal cells of the motor cortex (Troost et al., 1992).
Moreover, cystatin C-containing Bunina bodies are found in
the cell bodies of motoneurons in ALS (Okamoto et al.,
1993; Sasaki and Maruyama, 1994). Some breakdown products of abnormal proteins caused by oxidative stress called
ubiquitinated inclusion bodies (UIBs), are also implied in
the pathogenesis of ALS (Alves-Rodrigues et al., 1998).
Fragmentation of the Golgi apparatus (Fujita et al., 2000;
Fujita et al., 2002; Gonatas et al., 1998), mitochondrial
vacuolization (Okamoto et al., 1990) and ultrastructural

abnormalities of synaptic terminals (Sasaki and Iwata,
1996) are other neuropathological features of ALS.
Approximately 20% of ALS patients also have signs and
symptoms of frontotemporal dementia such as cortical atrophy including the frontal and temporal lobes (Nakano,
2000), hippocampus and amygdala (Wilhelmsen et al.,
2004), spongiform change in the neocortex, and UIBs in the
substantia nigra (Al-Sarraj et al., 2002). Furthermore, the
presence of crescent shaped inclusion-type UIBs in the
neostriatum has been found to be a feature specific to
ALS-frontotemporal dementia, and not occurring in a variety of other neurodegenerative disorders including Pick’s
disease, Parkinson’s disease, and Alzheimer’s disease (Kawashima et al., 1998). UIBs are found in ALS patients in the
dentate gyrus, frontal and parietal neocortices, anterior cingulate gyrus, hippocampus, parahippocampal gyrus, amygdale and neostriatum. The density and distribution of these
inclusions was higher in cognitively-impaired ALS patients
(as defined by poor performance on neuropsychological
testing) than in unimpaired individuals (Kawashima et al.,
1998; Wilson et al., 2001). The cognitively impaired patients also had UIBs in the temporal, occipital, and entorhinal cortices, posterior cingulate gyrus, caudate, and putamen. Computerized morphometry revealed a 25% reduction
in the pyramidal neuronal density in layer V of the premotor
cortex, dorsolateral prefrontal cortex, and anterior cingulate
cortex compared with age-matched controls (Maekawa et
al., 2004). This is particularly relevant in the context of
findings from positron emission tomography neuroimaging
which identified decreased binding of the GABAergic ligand (11C)-flumazenil in the prefrontal cortex (Lloyd et al.,
2000; Turner et al., 2005) and increased microglial activation (implicated in mechanisms of neuronal cell death) in
the dorsolateral prefrontal cortex (Turner et al., 2004).
1.2. Spatiotemporal changes in ALS neuropathology
Dissecting the spatiotemporal changes in pathology is
key to understanding the molecular mechanism(s) involved
in ALS. From a spatial perspective, the notion that ALS
affects only the motoneurons while sparing the central nervous system was refuted when neuropathological examination showed ubiquitin-immunoreactive but tau-negative inclusions in the frontotemporal cortex, hippocampus, and
dentate gyrus (Jackson and Lowe, 1996). To determine
where and when the pathological changes of motoneuron
disease begins, Fischer and colleagues (Fischer et al., 2004)
performed a comprehensive spatiotemporal analysis of disease progression in SOD1G93A mice. Quantitative pathological analysis was performed in the same mice at multiple
ages at neuromuscular junctions (NMJs), ventral roots, and
spinal cord. Mice became clinically weak at 80 days and
died at 131 ⫾ 5 days. At 47 days, 40% of end plates were
denervated whereas there was no evidence of ventral root or
cell body loss. At 80 days, 60% of ventral root axons were
lost but there was no loss of motoneurons. Motoneuron loss
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Fig. 1. Muscle innervation. An illustration of a normal motor unit showing
axons leading to motor end plates (neuromuscular junctions) on muscle cells.
(Taken from http://www.biology.iastate.edu/Courses/212L/New%20Site/31%
20MUscle%20&%20Skeletal%20systems/muscle%20skeletal%20index.
htm). Photos and layout by Linda Westgate, Warren Dolphin, and Mark
A. Mangum.

was well underway by 100 days. Microglial and astrocytic
activation around motoneurons was not identified until after
the onset of distal axon degeneration. Thus, in this animal
model of human ALS, motoneuron pathology begins at the
distal axon and proceeds in a “dying back” pattern. This is
supported by the denervation and reinnervation changes in
muscle but normal-appearing distal motoneurons following
autopsy of a reported ALS patient (Fischer et al., 2004).
1.3. The neuromuscular junction and its dismantling in
ALS
The basic unit of movement is comprised of skeleton,
muscles connected to skeleton, and nerves connected to the muscles. A motor unit consists of 1 motor neuron in the anterior horn
of the spinal cord, its axon, and all the muscle fibers innervated
by the branches of the axon (Fig. 1). The axon of the nerve
terminates on the muscle fibers at the NMJ. The number of
motor units that are active in a muscle at any 1 time
determines the level of performance of the muscle. Thus
each functional NMJ determines the motor ability.
It has been demonstrated that neuromuscular deficits in
ALS do not result from motoneuron cell death but rather
from loss of axonal integrity. As mentioned above, in the
SOD1G93A transgenic mouse model, motor unit numbers in
fast-twitch tibialis anterior, extensor digitorum longus, and
medial gastrocnemius muscles decline from 40 days of age,
40 –50 days before reported overt symptoms and motoneuron loss (Hegedus et al., 2007; Kennel et al., 1996). Motor
unit numbers fall after overt symptoms in the slow-twitch
soleus muscle (Hegedus et al., 2007). Similarly, the fact that
end plates are denervated much earlier than the axons and
the cell body loss during the pathogenesis of ALS as described in SOD1G93A mice (Fischer et al., 2004), gives
ample indication that the degenerative process in ALS starts
at the NMJ. In canine motoneuron diseases, functional mo-
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tor unit failure precedes neuromuscular degeneration (Balice-Gordon et al., 2000).
Early muscle-specific decline has been correlated to selective preferential vulnerability of large, fast motor units,
innervated by large motoneurons. Large motoneurons appear to be the most vulnerable in ALS with die-back occurring prior to overt symptoms (Hegedus et al., 2007). Subsequently, it was found that disease progression in fast-twitch
muscles of SOD1G93A mice involves parallel processes: (1)
gradual selective motor axon die-back of the fast fatigable
motor units that contain large type IIB muscle fibers, and of
fatigue-intermediate motor units that innervate type IID/X
muscle fibers; and (2) activity-dependent conversion of motor units to those innervated by smaller motor axons innervating type IIA fatigue-resistant muscle fibers (Hegedus et
al., 2009).
Studies that have used strategies to preserve the NMJ in
ALS models invariably show a delay in disease progression
(Dobrowolny et al., 2005; Ferri et al., 2003; Gifondorwa et
al., 2007; Li et al., 2007; Rouaux et al., 2007; Storkebaum
et al., 2005; Suzuki and Svendsen, 2008; Suzuki et al., 2007,
2008). Conversely, prevention of neurite outgrowth promotes denervation in an ALS model (Jokic et al., 2006).
There is conflicting evidence as to whether degenerative
signals emanate from the motoneuron itself, or from the
muscle. It has been shown that suppression of hSOD1G93A
expression within muscle alone is insufficient to maintain
grip strength or affect disease onset or survival, but that
suppression of hSOD1G93A expression in both motor neurons and muscle is sufficient to maintain grip strength
(Miller et al., 2006). Moreover, this group found that follistatin induced inhibition of myostatin, produced sustained
increases in muscle mass, myofiber number, and fiber diameter, but these increases did not affect survival. Conversely, a mouse model of muscle restricted mitochondrial
defect (similar to the hypermetabolism found in ALS) has
been shown to generate motor neuron degeneration (Dupuis
et al., 2009). Transgenic mice with muscular overexpression
of uncoupling protein 1, a potent mitochondrial uncoupler,
displayed age-dependent deterioration of the NMJ that correlated with progressive signs of denervation, grip strength,
and a mild late-onset motor neuron pathology.
Together, these data indicate that understanding the molecular events that promote the degeneration and dismantling of NMJ is crucial to understanding the underlying
cause of ALS and is a prerequisite for identifying appropriate treatment strategies. The important question therefore is
what molecular events lead to the deterioration of the motoneuron terminals at the NMJ? Factors produced by either
the muscles or motoneurons that impact the NMJ might be
considered prime candidates in the molecular pathology of
the disease. What are these factors, and how are they regulated and how do they affect the normal molecular signaling and trafficking at the NMJs?
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2. The lactate dyscrasia hypothesis of ALS
What is interesting about many patients with ALS is that
the function of the eye muscles is spared. Understanding
what is different about the eye muscles compared with other
muscles might therefore throw light on what causes skeletal
muscles to dysfunction. One noticeable characteristic of the
ocular nerves and muscles is that they use lactic acid as a
metabolic substrate to sustain function and therefore do not
become fatigued by high lactic acid, unlike skeletal muscles
(Andrade and McMullen, 2006). Thus, lactate is a metabolic
substrate that sustains extraocular muscle function and prevents muscle fatigue suggesting that these muscles have
high lactate turnover (i.e., the molecular machinery to convert lactate to pyruvate). Supporting this, lactate dehydrogenase (LDH) activity is detected in oculomotor neurons
(Hayashi, 1987) and in eye muscles (Kahan and Juhasz,
1976). Alternatively, it is possible that lactate is also removed from the nerves/muscles via a lactate shuttle (muscle-neuronal lactate shuttle; MNLS), like the recently proposed astrocyte-neuronal lactate shuttle (Erlichman et al.,
2008; Mangia et al., 2009). We therefore propose that an
MNLS exists to maintain lactate homeostasis between muscles and motoneurons (the neuromuscular unit) and that
dysregulation of the MNLS results in lactate assimilation in
the NMJ leading to cellular stress, toxicity, and subsequent
degeneration. The lack of neurotransmission would be expected to lead to muscular atrophy. Similarly, excess lactate
accumulation in myocytes also may promote muscle degeneration, although it might be expected that peripheral motoneurons are more susceptible to high lactate levels than
peripheral muscles. Progressive muscular atrophy is another
disease where dysregulation of lactate homeostasis could
lead to motoneuron degeneration with subsequent rapid
muscular atrophy (Ince et al., 2003).
The loss of lactate homeostasis and subsequent death of
motoneurons may create a vicious cycle whereby the remaining muscle fibers are required to work harder to compensate for normal muscle function, producing more lactate
and/or other toxic radicals inducing further motor neurotoxicity that leads to further neuronal degeneration and death.
This would explain the exponential progression of ALS
leading to paralysis.
2.1. The molecular model
We propose the existence of an MNLS to maintain lactate homeostasis at the NMJ (Fig. 2). We also anticipate that
this shuttle is an adenosine triphosphate (ATP)-dependent
shuttle operating at the NMJ between the muscle cell and
the nerve terminal to tightly regulate the flow of lactate from
the muscle to the neuron (or vice versa). The activity of this
shuttle is dependent on both the energy state and the threshold level of lactate tolerance of the muscle cell and the
neuron constituting the NMJ. Because the energy state of a
cell is dependent upon the generation of ATP, we propose a

molecular mechanism involving glycolysis, the tricarboxylic acid (TCA) cycle and the respiratory chain, the main
metabolic players of which include lactate, malate, oxaloacetate, citrate, and aspartate. The mechanism can be explained as follows. Under normal cellular conditions, the
respiratory chain provides the proton needed for the transport of aspartate from mitochondria to the cytosol via the
aspartate shuttle (aspartate is otherwise impermeable to the
mitochondrial membrane). The aspartate entering the cytosol can be converted to oxaloacetate by cytoplasmic aspartate aminotransferase. This cytoplasmic oxaloacetate
(also impermeable to mitochondrial membrane) is converted to malate by cytoplasmic malate dehydrogenase and
the malate thus formed can be converted to pyruvate by
malic enzyme. The oxaloacetate can also be converted to
phosphoenolpyruvate by phosphoenolpyruvate carboxylase
present in the cytoplasm. The phosphoenolpyruvate can
then be converted to pyruvate by pyruvate kinase. Pyruvate
can be converted to lactate by the activity of cytoplasmic
LDH. Pyruvate also can combine with acetyl CoA and can
be fed into the TCA cycle along with oxaloacetate via the
pyruvate dehydrogenase complex in the mitochondria to
generate citrate. Citrate, via a series of reactions in the TCA
cycle can regenerate oxaloacetate and malate. Oxaloacetate
can be converted to aspartate in the mitochondria by aspartate aminotransferase. The malate and citrate can either
diffuse, or are carried, across the mitochondrial membrane
by carrier proteins (Fig. 2). This whole series of metabolic
reactions occurs in both muscle cells and motoneurons constituting the NMJ. Thus, under normal conditions, lactate
levels are kept under tolerable levels at the NMJ by: (1)
conversion of lactate to pyruvate; (2) normal mitochondrial
function for the generation of protons and ATP; and (3) the
activity of the ATP-dependent MNLS.
Dysfunction of the respiratory chain and the failure to
contribute protons required for the translocation of aspartate
from the mitochondria to the cell cytoplasm would result in
the accumulation of aspartate in the mitochondria. This
prevents the conversion of oxaloacetate to aspartate. The
accumulated oxaloacetate will therefore be increasingly
converted to malate or citrate which either diffuses or is
transported into the cytoplasm by nonenergy-dependent carboxylate carriers for conversion to pyruvate (Fig. 2). This
continual accumulation of pyruvate leads to its active conversion to lactate by cytoplasmic LDH for the maintenance
of (limited) ATP generation via glycolysis (Fig. 2). A decrease in respiratory function would directly impair the
energy-dependent transport of lactate, leading to its accumulation in the NMJ, muscle, and/or nerve axon. The accumulation of pyruvate in the cytoplasm also would limit
flux through the normal glycolytic pathway for the generation of ATP and protons. Mitochondrial dysfunction and the
accumulation of lactate are therefore expected to impact the
neuron to a greater extent than the myocyte which is expected to be more tolerant to high concentrations of lactate.
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Fig 2. Molecular model for amyotrophic lateral sclerosis (ALS) pathogenesis. The model proposes that failure of the adenosine triphosphate (ATP)-dependent muscle
neuronal lactate shuttle (MNLS ⫺ hypothetical) due to respiratory chain dysfunction leads to lactate toxicity and consequent dismantling of the neuromuscular
junction (NMJ) in ALS. In essence, when the respiratory chain can no longer contribute protons required for the translocation of aspartate from the mitochondria
to the cell cytoplasm, aspartate accumulation in the mitochondrion prevents the conversion of oxaloacetate to aspartate by aspartate aminotransferase (1).
Accumulated oxaloacetate is increasingly converted to malate by mitochondrial malate dehydrogenase (2) or citrate by citrate synthase (3). Citrate itself can be
converted to malate by a series of tricarboxylic acid (TCA) cycle enzymes (4) such as aconitase, isocitrate dehydrogenase, ␣-ketoglutarate dehydrogenase, succinyl
CoA synthase, succinate dehydrogenase and fumarase. The malate and citrate formed either diffuse or are carried to the cytoplasm by nonenergy-dependent
dicarboxylate and tricarboxylate carriers for conversion to pyruvate. In the cytoplasm, malate is converted to oxaloacetate by malate dehydrogenase (2) and citrate
is cleaved to oxaloacetate by citrate lyase (5). The oxaloacetate thus generated in the cytoplasm is converted to phosphoenolpyruvate by phosphoenolpyruvate
carboxykinase (6) or malate by malate dehydrogenase (2). Cytoplasmic phosphoenolpyruvate and malate are converted to pyruvate by pyruvate kinase (7) and malic
enzyme (8), respectively. Pyruvate accumulation will inhibit further glycolysis (10), and anaerobic metabolism will promote pyruvate conversion to lactate by
cytoplasmic lactate dehydrogenase (9). The inhibition of the conversion of oxaloacetate to aspartate also will promote glutamate accumulation (because the
conversion of glutamate to ␣-ketoglutarate by mitochondrial glutamate dehydrogenase is coupled to the conversion of oxaloacetate to aspartate; Lehninger et al.,
1993). The accumulation of glutamate may promote excitotoxicity. These reactions occur in both nerve and muscle cell. Thus, when the energy-dependent shuttles
can no longer operate, toxic levels of lactate and glutamate accumulate in the nerve terminal and NMJ, leading to dysfunction, degeneration of nerve endings and
subsequent nerve terminus dysjunction or dismantling from the muscle cell at the NMJ. This loss of NMJs places further ‘strain’ on remaining muscle-nerve units
that attempt to compensate to provide normal function, leading to a vicious cycle of increased lactate production and neurotoxicity.

The inhibition of the conversion of oxaloacetate to aspartate also leads to the accumulation of glutamate (as the
conversion of glutamate to ␣-ketoglutarate by glutamate
dehydrogenase in the mitochondria is coupled to oxaloace-

tate to aspartate conversion; Lehninger et al., 1993). Glutamate is known to induce lactate production (Mendelowitsch
et al., 2001) by driving aspartate production and subsequently pyruvate and lactate production as discussed above
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(Fig. 2). Glutamate also is known to compromise the respiratory function of mitochondria (i.e., inducing Ca2⫹ accumulation and increasing reactive oxygen species (ROS)
(Urushitani et al., 2001) and inhibiting proton generation for
aspartate transport which leads to excitotoxicity. Thus,
when the MNLS fails to shuttle lactate due to a lack of ATP,
lactate and glutamate accumulation would lead to degeneration of the nerve endings (Vijayvergiya et al., 2005), dysfunction of the NMJ, and axonal toxicity. The loss of NMJ
would lead to a compensatory overactivity of the remaining
NMJ and muscle fibers, resulting in further increases in
lactate production and/or other toxic radicals, with this
vicious cycle inducing further motor neurotoxicity that
leads to muscle atrophy and eventually chronic paralysis.
2.2. Evidence for the molecular model
Evidence supporting the MNLS model includes: (1) the
concentration of serum lactic acid is higher in persons with
ALS (2.77 ⫾ 0.79 mmol/L) and chronic denervated nonALS patients (2.79 ⫾ 1.29 mmol/L) compared with controls
(1.48 ⫾ 0.49 mmol/L) (Siciliano et al., 2001); (2) lactic acid
can induce death in neurons (Nedergaard et al., 1991); (3)
increased lactate concentrations have been reported in other
neurodegenerative conditions such as Huntington disease
(Bowling and Beal, 1995) as well as in models of severe and
mild brain injury (Ramonet et al., 2004); (4) neuroprotective
drugs like nizofenone that block lactate accumulation are
used to treat other neurodegenerative diseases (Matsumoto
et al., 1994); (5) lactate metabolism in ALS is associated
with glutamate excitotoxicity related to neuronal degeneration (Shobha et al., 2007); (6) mitochondrial oxidative phosphorylation is dysfunctional in SOD1G93A transgenic mice
(Jung et al., 2002; Mattiazzi et al., 2002; Vijayvergiya et al.,
2005); (7) the malate-aspartate shuttle is inhibited in
hSOD1G93A expressing cells (Mali and Zisapels, 2008) and
this may explain the elevated levels of lactate and the
damage to neurons (Mali and Zisapels, 2008); (8)
hSOD1G93A-expressing cells showed increased concentrations of cytoplasmic malate dehydrogenase messenger ribonucleic acid (mRNA), malate, and lactate compared with
noninduced or wild-type-hSOD1-expressing cells (Mali and
Zisapels, 2008); (9) the mitochondrial NADH/NAD⫹ ratio
is elevated in hSOD1G93A-expressing cells indicating an
increased conversion of oxaloacetate to malate in the mitochondria by NADH-dependent mitochondrial malate dehydrogenase MDH (Mali and Zisapels, 2008); (10) impairments in the malate-aspartate shuttle which controls the
brain mitochondrial NADH/NAD⫹ balance is known to
drive anaerobic metabolism (particularly damaging to neurons) as well as vulnerability to impairments of glycolytic
pathways (Mali and Zisapels, 2008); (11) impaired oxidative metabolism and accumulation of lactate was reported in
exercising ALS patients (Siciliano et al., 2001); and (12)
functional motor unit failure precedes neuromuscular de-

generation in motoneuron disease (Balice-Gordon et al.,
2000; Fischer et al., 2004).
3. What derails lactate homeostasis leading to
neuromuscular junction toxicity?
ALS is an age-related disease; the cause of ALS must
therefore be related to the aging process. Because the downstream cause of ALS is the loss of NMJ and motoneurons,
understanding what signals regulate the balance between the
formation of motoneurons (innervation) and loss of motoneurons (denervation) is critical to identifying the upstream signals that promote ALS. It is known that denervated muscle is readily reinnervated, whereas innervated
muscle cannot be hyperinnervated (Frank et al., 1975; Sanes
and Covault, 1985). Recent evidence suggests that a compensatory increase in neuromuscular synapse regeneration
in ALS mediated by the skeletal muscle-specific micro
ribonucleic acid (microRNA), miR-206 that modulates fibroblast growth factor signaling and myogenin expression,
is insufficient to compensate for the damage induced by
mutant SOD1 (Williams et al., 2009). We propose that at a
critical threshold where denervation outpaces reinnervation,
a vicious cycle is established where the remaining innervated muscle fibers are required to work harder to compensate for normal function, and in doing so produce toxic
lactate concentrations which induces further denervation
and neuronal death.
The question therefore becomes what signals promote
innervation and what promote denervation, and how do
these change with aging? Because innervation is driven by
sex steroids (in particular estrogens and progestagens),
changes in sex steroids with aging may prevent appropriate
reinnervation in those individuals who produce elevated
lactate/glutamate (i.e., those containing a mutation in SOD1
or other associated metabolic pathway genes as described
above for example). This section will present evidence for
the genetic and geno-gerontological (i.e., the genetic regulation of aging processes) regulation of lactate homeostasis
that can explain the neuromuscular pathophysiology of
FALS and SALS.
3.1. Genetic-linked alterations in lactate homeostasis
underlying FALS
Genetic alterations in SOD1 have been identified in
20%–25% of those with FALS (Cudkowicz et al., 1997).
Although loss of catalytic hSOD1 activity has been implicated and mitochondrial ROS is associated with the mechanism underlying denervation-induced atrophy (Muller et
al., 2007) in familial ALS, the nature of the toxicity is
poorly understood (Carri et al., 1997; Kruman et al., 1999;
Rizzardini et al., 2005). Evidence for mutations in SOD1 as
driving the pathogenesis of ALS has been reported in cell
systems and mice overexpressing the hSOD1G93A protein as
described above (Jung et al., 2002; Mali and Zisapels, 2008;
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Mattiazzi et al., 2002; Vijayvergiya et al., 2005). These systems suggest that FALS-related mutations alter lactate homeostasis leading to the pathophysiology of FALS.
Suppression of hSOD1G93A expression within muscle
alone is insufficient to maintain grip strength or affect disease onset or survival (Miller et al., 2006). Suppression of
hSOD1G93A expression in both motor neurons and muscle
was sufficient to maintain grip strength. The requirement for
reduction of the expression of hSOD1G93A in both muscle
and motoneurons to effect an increase in muscle strength
suggests that decreases in the aberrant activity of this protein in all cell types is required to reverse the dysfunctional
mitochondrial oxidative phosphorylation (Jung et al., 2002;
Mattiazzi et al., 2002; Vijayvergiya et al., 2005) and malateaspartate shuttle inhibition in hSOD1G93A expressing cells
(Mali and Zisapels, 2008), and that lactate production in the
motoneuron may preferentially effect disease progression.
An analysis of genetic alterations in enzymes involved in
pyruvate and lactate production and removal, and the TCA
cycle, including ␣-ketoglutarate dehydrogenase complex
along with the glycolytic partner LDH might give further
insights into the key molecular candidates involved in the
development of FALS.
3.2. Genetic and age-linked alterations in lactate
homeostasis underlying SALS
The mean age of onset for SALS is ⬃ 60 years
(Wijesekera and Leigh, 2009), and is strongly suggestive of
an aging component in the onset of this sporadic form of the
disease. This is supported by studies in the mouse model of
ALS (hSOD1G93A mutant mouse). The magnetic resonance
imaging signal intensities of nucleus V, VII, XII, and nucleus ambiguus of these mice show an age-dependent increase starting around day 60, parallel to the first behavioral
signs of motoneuron disorder (Angenstein et al., 2004).
Also, the age-related progression of motor unit loss, adaptive sprouting (reinnervation of the denervated end plates),
maladaptive sprouting, and continuing recession of nerve
terminals during normal aging is extremely rapidly accelerated in ALS (Gordon et al., 2004).
Nearly 3 decades ago Appel (1981) hypothesized that
ALS may be related to steroid hormone/receptor deficiencies and that neurotrophic hormones acting at the synapse
may be critical in maintaining the neural networks that are
affected in ALS. Little research has been performed since
on the role of hormonal signaling with regard the pathogenesis and progression of ALS. We summarize below what is
known about sex-linked hormonal involvement in ALS.
The slight male prevalence (male:female ratio approximately 1.5:1; Wijesekera and Leigh, 2009) in the etiology of
ALS supports the possible involvement of a sex-linked
hormonal component to the pathogenesis of ALS, as proposed for other neurodegenerative diseases (Atwood et al.,
2005; Vadakkadath Meethal and Atwood, 2005). An early
study indicated a gender-related specificity in the ability of
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thyrotropin-releasing hormone to potentiate the monosynaptic reflex (Miller and Warnick, 1989). While castration in
male neonatal rats lowered the sensitivity to thyrotropinreleasing hormone, testosterone treatment restored that sensitivity. In this respect, there is a significant decrease in free
testosterone levels in ALS patients (Militello et al., 2002).
Interestingly, the female advantage toward ALS disappears
with age (Haverkamp et al., 1995). In animal studies using
the hSOD1G93A transgenic mouse, treatment of ovariectomized females with 17␤-estradiol did not delay the onset of
disease, but prevented progression of ALS motor dysfunctions as shown by extension reflex test for a limited time
window (Choi et al., 2008). Importantly, 17␤-estradiol
treatment rescued the life spans in ovariectomized females
(Choi et al., 2008). Moreover, the presence of the “slow
Wallerian degeneration” (Wld(S)) gene, shown to be protective in numerous models of axonal degeneration, prolongs survival preferentially in female mice carrying
SOD1G93A (Fischer et al., 2005). These observations reinforce the role of sex steroids in the maintenance of normal
motoneuron function and throw light on their potential to
avert ALS pathogenesis during aging.
That sex steroids are involved in the etiology of ALS is
supported by numerous studies indicating that sex steroids
are essential for normal brain function; they are neuroprotective, and promote neurogenesis, neuronal survival, and
normal cognitive function (reviewed in Bates et al., 2005;
Gleason et al., 2005; Simpkins et al., 2005; Vadakkadath
Meethal and Atwood, 2005). In particular, progestagens
have been demonstrated to promote embryonic neurogenesis (neurulation) (Gallego, et al., 2009; Gallego, et al.,
unpublished results available at: http://hdl.handle.net/10101/
npre.2008.2671.1) and neural differentiation in vitro (Brewer
et al., 1993) and in vivo (Wang et al., 2005). Progestagens and
estrogens are primary hormonal signals that regulate neuronal
growth and differentiation (Gould et al., 2000), promoting
neurite development and migration that lead to changes in
synaptogenesis (Leranth et al., 2002; Masumoto et al., 1991;
McEwan et al., 1996; Simerly, 2002). As part of these
differentiation processes, sex steroids are known to modulate growth of dendrites and dendritic spine density, with the
loss of sex steroids generally resulting in decreased spine
density (Leranth et al., 2003; Woolley and McEwen, 1993).
A decline in peripheral (i.e., gonads, adrenals, or other
tissues) and/or local (central nervous system) sex steroid
production might therefore be expected to promote motoneuron degeneration. Dysregulation of the hypothalamicpituitary-gonadal (HPG) axis with aging has been postulated to drive aging-related diseases via alterations in cell
signaling throughout the body (Atwood et al., 2005; Bowen
and Atwood, 2004; Vadakkadath Meethal and Atwood,
2005). This altered cell cycle signaling, resulting from the
decline in sex steroid and inhibin production and elevation
in gonadotropin-releasing hormone, gonadotropin, and activin signaling, has been shown to drive postreproductive
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degenerative mechanisms involved in Alzheimer’s disease
(Bowen et al., 2004; Casadesus et al., 2006), osteoporosis
(Sun et al., 2006), and blood-brain barrier integrity and
associated diseases such as stroke (Wilson et al., 2008).
The abrupt loss of serum sex steroids with reproductive
senescence not surprisingly correlates with an increased
prevalence of cognitive disease in women (Brookmeyer et
al., 1998; Jorm et al., 1987; McGonigal et al., 1993), while
sex steroid replacement therapy decreases the incidence
(Henderson et al., 1994) and delays the onset of cognitive
decline in women and men (reviewed in Gleason et al.,
2005). Interestingly, ALS is associated with the loss of
cognitive-behavioral competency with progressive involvement of the prefrontal cortex and, in a few instances, profound dementia (Montgomery and Erickson, 1987), supportive of a hormonal component to the disease process.
That these hormones could impact the NMJ is evidenced
by the fact that receptors for sex steroids are localized in
various muscles, neurons, and neuromuscular junctions of
vertebrate and invertebrates (Kimura et al., 1993; Pelletier,
2000). Sex steroid receptors are expressed in smooth muscle
cells (Haynes et al., 2002) and respiratory motoneurons of
both male and female rats (Behan and Thomas, 2005).
Interestingly, sex hormone receptors are present in motor
neurons of the rat embryo spinal cord (Rakotoarivelo et al.,
2004). There is an enrichment of androgen receptor (⫹)
myonuclei and fibroblasts proximate to neuromuscular junctions in the skeletal muscle of the rat, suggesting that androgen receptors at muscle synapses may selectively regulate synapse-specific genes important for the survival and
growth of motoneurons (Monks et al., 2004). Castration
reduced the proportion of androgen receptor fibroblasts in
muscles and testosterone treatment prevented these effects
of castration. There are also evidences for the androgen
regulation neuromuscular junction structure and function in
some of the sexually dimorphic muscles of the frog Xenopus
laevis (Brennan and Henderson, 1995). In addition, there is
strong evidence for the fact that testosterone via its receptor
may regulate the coupling mechanisms between Ca v2.2
channels and neurotransmitter release at the neuromuscular
junctions of bulbocavernosus and levator ani muscles motoneurons (Nudler et al., 2005). Earlier results have shown
that testosterone deprivation reduces the junctional acetylcholine receptor density and androgens modulate endplate
size and acetylcholine ACh receptor density at synapses in
rat levator ani muscle (Bleisch and Harrelson, 1989; Bleisch
et al., 1982; Souccar et al., 1991). Finally, in Xenopus
laevis, females have stronger laryngeal synapses than males,
and synapse strength is estrogen dependent and the laryngeal neuromuscular synapse is the final effector for sexually
differentiated song production. Immunocytochemistry and
Western blots confirmed the presence of estrogen receptor
protein in laryngeal muscle fibers (Bleisch et al., 1982).
Together, these observations suggest a prominent role for

sex steroids in the normal functioning of neurons and muscles in the NMJ.
3.3. Glutamate/lactate metabolism and the sex hormones
Increased glutamine synthetase, plasma glutamate levels,
defective glutamate metabolism, and glutamate excitotoxicity have been strongly implicated in the pathogenesis of
ALS (Andreadou et al., 2008; Bos et al., 2006; Ionov,
2007). The exposure of SALS-serum to rat motoneurons
increases their LDH activity and depletes the glutamate
transporter GLT-1 and the cells subsequently die presumably due to increased levels of glutamate triggering glutamate-mediated toxicity (Shobha et al., 2007; Vijayalakshmi
et al., 2009). Interestingly, this observation ties glutamate
toxicity to lactate levels. One of the earlier studies showing
increased LDH activity in the hypothalamic nuclei of adult
neonatally androgenized female rats (Packman et al., 1977)
clearly gave evidence for the linkage of androgen signaling
to lactate oxidation in brain. In this regard, the endogenous
steroid hormones such as aldosterone, progesterone, and
testosterone showed neuroprotective effects from glutamate
neurotoxicity in various neuronal cell cultures (Bhavnani et
al., 2003; Ogata et al., 1993; Zhao et al., 2002). Interestingly, Mendelowitsch et al. (2001) showed that glutamate
induces lactate production, intake of lactate by neurons, and
that the neuroprotective effect of 17␤-estradiol requires the
activities of lactate transporters. Also, the lactate transfer
between the astrocyte and neurons is demonstrated to be
potentiated by glutamatergic activity (Pellerin, 2008). In
addition, we propose that the inhibition of the conversion of
oxaloacetate to aspartate can lead to the accumulation of
glutamate as the conversion of glutamate to ␣-ketoglutarate
by glutamate dehydrogenase in the mitochondria will not
occur because this reaction is coupled to oxaloacetate to
aspartate conversion (Lehninger et al., 1993). Thus, it is
reasonable to conclude that: (1) glutamate and lactate production and their metabolism are tightly linked; (2) agedependent changes in reproductive hormones can play a role
in glutamate/lactate homeostasis in NMJs; (3) the functions
of sex hormones are linked to the lactate metabolism and
lactate transporters; (4) lactate transporters are important in
normal neuronal function; and (5) cellular energy failure
can result in the loss of MNLS function and the consequent
accumulation of lactate can lead to neurotoxicity and dismantling of the NMJ.
4. A multidrug therapy for the treatment of ALS
Based on the above model along with the other evidence
described above, therapeutic strategies for the treatment
ALS should incorporate drugs that: (1) maintain lactate
homeostasis in NMJs; (2) maintain mitochondrial function;
(3) halt damage to peripheral nerves; and (4) promote regeneration of peripheral nerves. Thus, combinations of
drugs that inhibit lactate accumulation at the NMJ, enhance
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respiratory chain function, and that are neurotrophic should
be most effective at halting the progression of ALS.
The existing treatment modalities partly support this
idea. Rilutek (riluzole; Sanofi-Aventis, Bridgewater, NJ),
the popular “antiglutamatergic” agent, remains the only
Food and Drug Administration (FDA) approved drug for
ALS treatment at present, decreasing the progression of
ALS, and increasing the survival of ALS patients by 4 –19
months (Radunovic et al., 2007). However, riluzole may not
be effective during advanced stages of the disease (Radunovic et al., 2007). Memantine, a noncompetitive Nmethyl-D-aspartate receptor antagonist, was recently found
to prolong the survival of SOD1G93A mouse model (Wang
et al., 2005), supporting glutamate toxicity in the pathogenesis of ALS.
There is generally no consensus on the effects of exercise
and ALS. While moderate exercise has been shown to have
beneficial effects in ALS, strenuous exercise (i.e., which
induces lactic acid) may have adverse effects (reviewed in
Miller et al., 2006). The balance between lactate production
and enhanced signaling for innervation following exercise
may explain these discrepancies.

5. Conclusions
We present a novel molecular model for the molecular
pathogenesis of ALS that involves an ATP-dependent
MNLS to maintain lactate homeostasis at the NMJ by
tightly regulating the flow of lactate from muscle to neurons
and visa versa. Failure of this shuttle is proposed to lead to
lactate assimilation in the NMJ leading to cellular stress,
toxicity, and subsequent degeneration. Future studies should
focus on the identification and characterization of the
MNLS and the mutational and endocrine factors that regulate MNLS function and dysfunction in ALS. Moreover,
age-related changes in hormones should be considered in
the etiology of the disease. Combination therapy composed
of drugs that inhibit lactate accumulation at the NMJ, enhance respiratory chain function, and that are neurotrophic
are predicted to be the most effective therapeutic strategy
for halting the progression of ALS.
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